Form 4: Cidara Therapeutics Executive Sells Shares to Cover Tax Obligations

Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, sold 909 shares of common stock to cover tax withholding obligations related to the vesting and settlement of RSUs.

Summary

• On September 11, 2024, Leslie Tari, the Chief Scientific Officer of Cidara Therapeutics, sold 909 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $11.6393, with individual transactions ranging from $11.61 to $11.64.
• Following the transaction, Tari directly owns 17,788 shares of Cidara Therapeutics common stock and indirectly owns 73 shares through a spouse.
• The reported number of securities have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
• Tari also acquired 200 shares pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale to cover tax obligations, which is neither particularly positive nor negative. It's a neutral event in terms of investment sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax obligations. Monitoring these transactions can provide insights into management's perspective on the company's value, although sales to cover taxes are generally less informative than discretionary sales.

Stakeholder Impact

• The stock sale could have a minor, temporary impact on the stock price, but is unlikely to significantly affect long-term shareholder value.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates